These findings certainly highlight the urgent need to track the evolution of exosomal PD-L1 at different time points after therapy, since the discrepancies observed among studies may be dependent on the time of testing and thus may reflect the evolution of tumor immune escape. The gene discussed is CD274; the disease is neoplasm.